Slide 1: electroCore: A Bioelectronic Medicine & Wellness Company
b2 20x electroCore’ A Bioelectronic Medicine & Wellness Company Nasdaq: ECOR
Slide 2: Forward Looking Statements
q Forward Looking Statements In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions
Slide 3: Investor Highlights
Investor . Revenue Highlights A Bioelectronic Medicine & Wellness Company $32.0 $25.2} Focused on Multiple Indications Large and Growing Opportunity’ 516.0) + FDA Cleared for the prevention and treatment of primary * $20 billion spent annually out-of-pocket for chronic pain headache in adults and ad
Slide 4: Bioelectronic Technologies
Bioelectronic Technologies Rx Products General Wellness General Wellness b4 Sex electroCore” NASDAQ: ECOR
Slide 5: gammaCore Sapphire
- $apphire™ # a oe 1st FDA-cleared non-invasive @) vagus nerve stimulator mE Fast acting, comfortable, easy to use hand-held option FDA Cleared for the prevention and treatment of primary headache in adults and adolescents No drug-drug interactions or drug-like side effects Can be used as a stand-al
Slide 6: Quell Technology
LEARN MORE Quell® Technology First and only high-dose wearable neuromodulation device for chronic pain FDA Authorized, non-invasive solution for fibromyalgia, a large, underserved market + ECOR expects to leverage its sales + Symptom relief-beyond reduction in pain channels, particularly the VA Hosp
Slide 7: Meet the Truvaga Vagus Nerve Stimulators
L ruvaga Meet Truvaga Our Products v Vagus Nerve Science Reviews Blog _— Support v oe Meet the Truvaga Vagus Nerve Stimulators SYVIQg, e rae @ @ e& Y Es ew Truvaga Plus Truvaga 350 F tzanw mone | LEARN MORE Transform the way you feel with Truvaga vagus nerve therapy. Our proven technology gently act
Slide 8: TAC-STIM
LEARN MORE TAC STI, Gs celerated Training Sustained Attention Reduced Fatigue ¢ Improved Mood e, treat, cure, or prevent any disease or NASDAQ: ECOR
Slide 9: Active Channels With Revenue Growth Opportunities
Active Channels With Revenue Growth Opportunities VA Hospitals US Commercial Driving Rx sales in the Department of Defense and Community Care Network through the $2.98 roughly 1,300 Department of Veterans Affairs and Military Treatment Facilities; TAM? Significant opportunity to add fibromyalgia off
Slide 10: Bioelectronic Technology - Pipeline of Possible FDA Clearances
Bioelectronic Technology - Pipeline of Possible FDA Clearances gammaCore is the SD Primary headache’ only FDA-cleared non-invasive VNS therapy in » mild Traumatic Brain Injury (mTBI) 2 primary headache » Symptoms of fibromyalgia’ » 3 Post-traumatic stress disorder (PTSD)? Quell is the first and » Ch
Slide 11: Broad Intellectual Property Portfolio
Broad Intellectual Property Portfolio electroCore owns all intellectual property on which the technology relies Expansive pioneering IP coverage of peripheral nerve stimulation and non-invasive, transdermal neuro- stimulation in the neck > 3 0 0 We have patent coverage extending beyond 2040: * Non-i
Slide 12: Strategic Pivots
Strategic Pivots ¢ Pivot 1: the NeuroMetrix Acquisition * Integration completed ahead of schedule * Revenue in our VA Channel exceeding expectations * Launch Quell for lower extremity pain under the Truvaga brand in early 2026 ¢ Pivot 2: strengthening our VA Hospital Channel * Carefully adding field
Slide 13: Revenue Growth
Revenue Growth Net Sales $ in thousands $32.0M 5-year TTM CAGR: 57% 55% $25,182 58% $16,030 $8,592 $5,451 $3,496 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025E* bs, *Guidance as of January 20, 2026 of $31.8 - $32.0 million SOx electroCore” NASDAQ: ECOR
Slide 14: Capitalization Table
Capitalization Table Fully diluted as of October 30, 2025 (in thousands) Common Shares* 7,996 Pre-Funded Warrants 883 Warrants 1,497 Average Exercise price = $5.31 Options 518 Average Exercise price = $32.56 Restricted and Deferred 589 RSUs/DSUs which vest through Stock Units September 2028 Total 11
Slide 15: Experienced Management Team
Experienced Management Team Thomas J. Errico, MD Dan Goldberger Joshua Lev Chairman, Founder and Chief Executive Chief Financial Principal Investor Officer Officer Peter Staats Chief Medical Officer Nicklaus RMS <TANT <x) usec Y Children’s » Hospital wellfleet seca pariners,inc ct }sounn surcicat =
Slide 16: electroCore: A Bioelectronic Medicine & Wellness Company
b2 20x electroCore’ A Bioelectronic Medicine & Wellness Company Nasdaq: ECOR
Slide 17: TAM Sources
TAM Sources Sources: VHA Data: + Migraine Is a Commonly Treated Condition Among Veterans (Nov. 2022) veterans/ . va. . nebi.nim.nih. iti ids Sleep Aids Market: BH 11738#: 20S ids % 20Mark 200verview, ket. 10% 20(2023% 20%2D% 202032). Mental Physical Performance: report#:~:text=The%20U.S.‘ 2 Practici